Moderna, Inc. (MRNA)
Moderna Eyes Cancer Vaccine Filing as It Expands Beyond COVID
Moderna NASDAQ: MRNA executives emphasized the company's evolution beyond COVID-19 vaccines during a discussion with Bernstein, highlighting its mRNA platform, personalized cancer vaccine program intismeran, rare-disease pipeline and plans to expand therapeutics development.
Moderna Climbs 6% as Cancer Vaccine Trade Extends a 137% Month; BioNTech and Novavax Edge Higher
Cancer vaccine momentum is doing the work for Moderna (NASDAQ:MRNA | MRNA Price Prediction) once again on Thursday, extending one of the sharpest one-month runs in large-cap biotech this year without a fresh disclosure attached to it.
Is Cancer the Turnaround Moderna Has Been Looking for Post-COVID?
Shares of Moderna MRNA have staged a remarkable comeback this year as investors increasingly warm to the possibility that the company can rebuild its business beyond COVID-19 vaccines. After becoming one of the biggest pandemic winners, Moderna struggled with sharply lower COVID-19 vaccine demand, declining revenues and mounting losses, sending its stock tumbling from its pandemic-era highs.
Moderna (MRNA) Ascends While Market Falls: Some Facts to Note
In the closing of the recent trading day, Moderna (MRNA) stood at $146.69, denoting a +1.89% move from the preceding trading day.
Moderna's AI-Built Cancer Vaccine Clears Phase 3 With Merck
Moderna built an artificial intelligence that reads a patient's tumor and decides what that patient's medicine should be. That approach just cleared its biggest test.
Moderna's Cancer Vaccine Win Fuels Broad Push Across Tumor Types
Moderna NASDAQ: MRNA President Stephen Hoge said the company's recently announced positive Phase III results for its investigational personalized cancer vaccine, intismeran, in adjuvant melanoma support a broader effort to use T-cell priming in multiple tumor types.
Moderna Rallies 8% on 2026 Melt-Up Momentum Even While BioNTech and Merck Stay Flat
Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is up 8% to $147.37 in Friday morning trading, a sharp single-name move on a session when biotech as a group is quiet and broader U.S. equities are only modestly higher.
MRNA Stock Soars 143% in a Month: Time to Buy, Hold or Sell?
Moderna stock surges 143% in a month on positive cancer therapy results, but competition and valuation raise key questions for investors.
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
Drug pricing is back on the front page, and healthcare investors have barely flinched. The White House's latest round of most-favored-nation pricing agreements brought nine more manufacturers into the fold, pushing the total to 26 companies covering 89% of the branded drug market.
Does Moderna's mRNA Flu Shot Face a New Challenge From GSK?
MRNA's newly approved mFlusiva faces a potential challenge as GSK advances an mRNA flu vaccine targeting two viral proteins.
Moderna: Massive Asymmetry About What The mRNA Is!
Moderna receives a speculative Strong Buy rating after phase 3 melanoma data strengthens its oncology platform thesis. MRNA's upside hinges on Intismeran's ability to scale across multiple tumor types, not just melanoma. The 50/50 partnership with Merck provides both distribution strength and shared economics for Intismeran.
Why Moderna's Cancer Vaccine Matters to Investors
Healthcare is moving away from the traditional model of mass-produced, one-size-fits-all treatments toward individualized therapies. This evolution in medicine aims to provide treatments that are not only more effective but also carry a lower risk of adverse side effects by aligning with a patient's unique biology.
